Trip.com Group (NASDAQ:TCOM) Bolsa

TRIP.COM GROUP LTD-ADR

Trip.com Group

Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 79% of sales from accommodation reservations and transportation ticketing in 2024. The rest of revenue comes from package tours and corporate travel. Before the pandemic in 2019, the company generated 25% of revenue from international travel, which is important to its margin expansion. Most of sales come from its domestic platform, but the company is expanding its overseas business. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Tongcheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.

New,York,,Usa,-,15,May,2020:,Trip.com,Mobile,App

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

PAYX

SOHU

TCOM

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este lunes: TCOM, PAYX, ZIM, SOHU y GSL.

5 acciones en el foco este lunes: TCOM, PAYX, ZIM, SOHU y GSL

Equities

Large Cap

Dividends

Buybacks

Movers

BEDZ

PowerShares Golden Dragon Halter USX China Portfolio

Trip.com reportó un BPA superior al esperado y un aumento en ingresos. Sin embargo, sus acciones caen antes de la apertura del mercado.

Acciones de Trip.com (TCOM) caen pese a sólidos resultados trimestrales

INTU

WDAY

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este martes: HD, KDP, TCOM, WDAY e INTU.

5 acciones en el foco este martes: HD, KDP, TCOM, WDAY e INTU

Trip.com Group Limited - American Depositary Shares

Trip.com Group Ltd

Citigroup analyst Vicky Wei downgrades Smart Share Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EM#NASDAQ">EM</a>) from Buy to Neutral and raises the price target from $1 to $1.25.

Downgrades

Price Target

Analyst Ratings

Citigroup Downgrades Smart Share Global to Neutral, Raises Price Target to $1.25

Needham analyst Ami Fadia reiterates Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) with a Buy and maintains $9 price target.

Reiteration

IMRX

Needham Reiterates Buy on Immuneering, Maintains $9 Price Target

Citigroup analyst Andres Cardona initiates coverage on Loma Negra Cia Industria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOMA#NYSE">LOMA</a>) with a Buy rating and announces Price Target of $16.

Initiation

LOMA

Citigroup Initiates Coverage On Loma Negra Cia Industria with Buy Rating, Announces Price Target of $16

Aurora Cannabis Q4 2025 EPS $(0.24) May Not Be Comparable To $0.11 Estimate, Sales $63.07M Beat $62.04M Estimate

HC Wainwright &amp; Co. analyst Matthew Caufield assumes Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) with a Buy rating and announces Price Target of $10.

ARDX

HC Wainwright & Co. Assumes Ardelyx at Buy, Announces Price Target of $10

LifeSci Capital analyst Charles Zhu initiates coverage on Crescent Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBIO#NASDAQ">CBIO</a>) with a Outperform rating and announces Price Target of $22.

CBIO

LifeSci Capital Initiates Coverage On Crescent Biopharma with Outperform Rating, Announces Price Target of $22

Benchmark analyst Cody Acree reiterates Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Buy and maintains $95 price target.

MRVL

Benchmark Reiterates Buy on Marvell Tech, Maintains $95 Price Target

LifeSci Capital analyst Cory Jubinville downgrades Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) from Outperform to Market Perform and announces $12 price target.

VERV

LifeSci Capital Downgrades Verve Therapeutics to Market Perform, Announces $12 Price Target

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 7.17%</li>
<li>UBS analyst Trung Huynh maintained a Neutral rating and increased the price target from $24 to $25 on April 30, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating on March 18, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) on June 6 announced in a press release the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) with its partner Pfizer.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest PFE <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0618">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0618"><img loading="lazy" decoding="async" width="910" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053555/image-280.png" alt="" class="wp-image-953567" style="width:608px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053555/image-280.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053555/image-280-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053555/image-280-768x711.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></a></figure>
<h3 class="wp-block-heading">Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.14%</li>
<li>Citigroup analyst Andrew Baum downgraded the stock from Buy to Neutral and cut the price target from $115 to $84 on May 14, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating with a price target of $115 on April 17, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: The U.S. Food and Drug Administration (FDA) on Friday approved Merck's Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (combined positive score of at least 1), as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest MRK <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0618">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0618"><img loading="lazy" decoding="async" width="917" height="825" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053627/image-281.png" alt="" class="wp-image-953569" style="width:590px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053627/image-281.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053627/image-281-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053627/image-281-768x691.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">DENTSPLY SIRONA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.16%</li>
<li>UBS analyst Kevin Caliendo maintained a Buy rating and cut the price target from $27 to $25 on May 9, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Mizuho analyst Steven Valiquette maintained a Neutral rating and lowered the price target from $21 to $18 on March 13, 2025. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On June 5, Dentsply Sirona priced an offering of $550 million of junior subordinated notes.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest XRAY <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0618">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0618"><img loading="lazy" decoding="async" width="922" height="821" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053656/image-282.png" alt="" class="wp-image-953570" style="width:581px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053656/image-282.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053656/image-282-300x267.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053656/image-282-768x684.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45970767/top-3-health-care-stocks-that-are-ticking-portfolio-bombs">Top 3 Health Care Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

Long Ideas

ARVN

XRAY

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Incannex Healthcare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, is pleased to announce that it has achieved database lock for the RePOSA Phase 2 clinical trial of IHL-42X, its lead drug candidate for obstructive sleep apnoea (OSA), on schedule as of 16 June 2025.
This marks a major milestone in the development of IHL-42X, confirming the completion of clinical data collection and enabling final statistical analysis to begin. The Company is on track to deliver top-line results in July 2025, reinforcing confidence in the program's momentum and execution.
The RePOSA Phase 2 trial is evaluating IHL-42X in patients with moderate to severe OSA who are unable or unwilling to use continuous positive airway pressure (CPAP). The proprietary fixed-dose combination therapy is designed to reduce apnoea episodes, improve sleep quality, and offer a patient-friendly alternative to current treatment options.
With over 900 million people affected by OSA worldwide and growing awareness of its impact on cardiovascular and metabolic health, IHL-42X is positioned to disrupt the treatment paradigm and deliver meaningful clinical benefit to a vastly underserved patient population.
This achievement builds on positive results from earlier studies and marks the next step in the Company's strategy to commercialise IHL-42X as a first-in-class, market-leading therapeutic solution for OSA. &nbsp;

IXHL

Incannex Healthcare Completes Database Lock For RePOSA Phase 2 Clinical Trial Of IHL-42X, Drug Candidate For Obstructive Sleep Apnoea

HC Wainwright &amp; Co. analyst Yi Chen assumes Eledon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELDN#NASDAQ">ELDN</a>) with a Buy rating and announces Price Target of $9.

ELDN

HC Wainwright & Co. Assumes Eledon Pharmaceuticals at Buy, Announces Price Target of $9

GRPN

Groupon To Exchange $170M Of 2026 And 2027 Notes For $244M Of New 2030 Convertible Notes With 50% Premium Conversion Price

BWMN

Bowman Selected As Lead Engineer For $24M Del Norte Water Upgrade, Secures $1.5M Contract

Summit Royalty Corp. ("Summit" or the "Company"), a private royalty and streaming company, is pleased to announce the successful acquisition of a portfolio of cash flowing royalties and stream (the "Portfolio") from IAMGOLD Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/IMG#TSX">IMG</a>) and its affiliates (collectively, "IAMGOLD") for total consideration of $17.5 million. Unless otherwise indicated, all $ amounts are expressed in US dollars.
Key Portfolio Assets
The key assets in the Portfolio include:
<ul>
<li>Bomboré Silver Stream (Ganzourgou Province, Burkina Faso) – a 50% silver stream on the operating Bomboré Mine owned and operated by Orezone Gold Corporation;</li>
<li>Pitangui Royalty (Minas Gerais, Brazil) – an $80/oz production royalty on the first 250 Koz of gold sold, and a 1.5% NSR royalty thereafter on the Pitangui project currently under development by Jaguar Mining Inc.;</li>
<li>Zancudo Royalty (Titiribi, Colombia) – a 0.5% NSR royalty on the operating Zancudo Mine owned and operated by Denarius Metals Corp.; and</li>
<li>Lavras do Sul Royalty (Rio Grande do Sul, Brazil) – a 3.0% NSR royalty on the over 5,000 Ha Lavras do Sul project owned by Lavras Gold Corp.</li>
</ul>
Acquisition and Financing Terms
Summit acquired the Portfolio comprising seven royalties and one stream from IAMGOLD through a purchase and sale agreement for total consideration of $17.5 million comprising cash consideration of $10 million and common shares of Summit (each, a "Share") valued at $7.5 million.
To satisfy the $10 million of cash consideration, Summit successfully raised over $13 million through a non-brokered private placement comprised of leading institutions and sophisticated retail investors.

TSX:IMG

Summit Royalty Acquires Portfolio Of Cash Flowing Royalties And Stream From IAMGOLD For Total Consideration Of $17.5M

New intellectual property builds on Palvella's multi-layered exclusivity strategy
Patent term expected through at least 2038
- (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PVLA#NASDAQ">PVLA</a>) <a href="https://www.globenewswire.com/Tracker?data=_BN-hzdBLmmdjUHZEQ0MfOnoi6AcBCapUKJ21MWBysUAcCHGjYy7p2-qXS0nJaTbwSX9gx_HbI3dygdxQLADiMaENFxV6Z-cYPQW1CwTSQw=">Palvella Therapeutics, Inc</a>. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration&nbsp;(FDA)-approved therapies, today announced that the United States Patent and Trademark Office (USPTO) issued patent No. 12,329,748 for claims related to the Company's lead product candidate QTORIN&#x2122; 3.9% rapamycin anhydrous gel (QTORIN&#x2122; rapamycin). The patent provides broad protection for the proprietary anhydrous topical composition and methods of use for QTORIN&#x2122; rapamycin.
"Our sixth issued U.S. patent marks another meaningful milestone in solidifying the exclusivity position of QTORIN&#x2122; rapamycin," said Wes Kaupinen, Founder and Chief Executive Officer of Palvella. "We're executing a multi-layered strategy to protect and maximize the long-term value of QTORIN&#x2122; rapamycin—anchored by strong intellectual property, proprietary formulation and manufacturing trade secrets, and regulatory exclusivities."
The newly granted U.S. patent encompasses a wide range of composition and method-of-use claims for QTORIN&#x2122; rapamycin and other mTOR inhibitors—including temsirolimus and everolimus—formulated in anhydrous compositions. It also covers treatment of a broad spectrum of dermatologic conditions, with emphasis on rare and difficult-to-treat diseases such as microcystic lymphatic malformations and venous malformations.
QTORIN&#x2122; rapamycin has been granted Breakthrough Therapy, Orphan Drug, and Fast Track Designations by the FDA for the treatment of microcystic lymphatic malformations. If approved, QTORIN&#x2122; rapamycin is expected to qualify for seven years of orphan drug market exclusivity in the U.S. Palvella has also been named an awardee of an FDA Orphan Products Grant from the FDA's Office of Orphan Products Development and is eligible to receive up to $2.6 million over the life of the grant to support the ongoing SELVA Phase 3 trial of QTORIN&#x2122; rapamycin.

Biotech

General

PVLA

Palvella Therapeutics Receives U.S. Patent Covering 0.1–20% Anhydrous Compositions Of Rapamycin And Other mTOR Inhibitors

BIIB

Biogen Launches Global Phase 3 BRAVE Study Of SKYCLARYS For Pediatric Friedreich Ataxia Patients Aged 2 To Under 16

Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer&nbsp;
FDA recommends inclusion of patients as young as 6 months – younger than Moleculin had proposed – to be allowed in the pediatric clinical study
Enrollment and dosing are ongoing in pivotal, adaptive design Phase 3 MIRACLE trial of Annamycin in adult patients with R/R AML; Initial data readout is on track for the second half of 2025
(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced it has received a written response from the Office of Oncologic Diseases - Pediatric Oncology, of the U.S. Food and Drug Administration (FDA) regarding the Company's Initial Pediatric Study Plan (iPSP), which was submitted after a June 2024 end-of-phase 1/2 meeting. The FDA has agreed to a single pediatric approval study in which Annamycin (also known as naxtarubicin) in combination with Cytarabine (also known as "Ara-C" and for which the combination of Annamycin and Ara-C is referred to as "AnnAraC") will be evaluated as second line therapy in pediatric patients with relapsed/refractory acute myeloid leukemia (R/R AML), a form of cancer.
"We continue to be encouraged by the potential of Annamycin to change the game when it comes to the most prevalent cancer therapies in use today. This is particularly important in pediatric oncology, where about 60% of children with cancer are treated with anthracyclines that present a high risk of causing heart damage. An independent expert's review of study data has shown no cardiotoxicity to date in 84 adult patients treated with Annamycin, which is why we're excited about moving forward in young children with cancer. Receiving this written feedback from FDA is a crucial step in the development of Annamycin for pediatric use and provides us with helpful insight as we continue to prepare for the launch of a pediatric trial, planned for the second half of 2027," said Walter Klemp, Chairman and CEO of Moleculin. "As our team works to address and implement FDA's feedback on our iPSP, we remain focused on the successful execution of our ongoing MIRACLE trial of AnnAraC in adult patients with R/R AML and look forward to initial data from that trial later this year."

MBRX

Moleculin Receives Positive FDA Feedback On Pediatric Study Plan For Annamycin In Children With R/R AML

Guidance

Nucor Sees Q2 EPS $2.55-$2.65

WestPark Capital analyst Casey Ryan maintains Innoviz Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVZ#NASDAQ">INVZ</a>) with a Buy and raises the price target from $2.22 to $2.53.

INVZ

WestPark Capital Maintains Buy on Innoviz Technologies, Raises Price Target to $2.53

Soluna Holdings, Inc. ("Soluna" or the "Company"), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>), a developer of green data centers for intensive computing applications, including Bitcoin mining and AI, today announced that it has signed a hosting expansion agreement with Blockware, one of North America's leading crypto mining infrastructure and services providers.
Following their <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.solunacomputing.com%2Fnews%2Fblockware-5mw%2F&amp;esheet=54277973&amp;newsitemid=20250618047710&amp;lan=en-US&amp;anchor=initial+5+megawatt+%28MW%29+deployment+in+April&amp;index=1&amp;md5=0d6b8ec6c6ce06cb996345b03913ab3a">initial 5 megawatt (MW) deployment in April</a>, Blockware is adding 3 MW of hosting capacity at Soluna's Project Dorothy 2 data center in Texas, bringing their total contracted footprint at the site to 8 MW.
Blockware's total deployment at Dorothy 2 now represents up to 8 MW and an estimated 450-550 PH/s of hashrate powered by renewable energy, further advancing both companies' commitment to sustainable blockchain infrastructure in the United States.
 &nbsp;
 &nbsp;

SLNH

Soluna Holdings Signs Hosting Expansion Agreement With Blockware; Now Totaling 8 MW of Sustainable Hosting Capacity

Press Releases

Trip.com Group Announces Changes in Board Composition

Trip.com Group Limited Reports Unaudited Fourth Quarter and Full Year of 2024 Financial Results

Offerings

Baidu Announces Proposed Offering of Exchangeable Bonds

Baidu Announces Pricing of US$2 Billion Offering of Zero Coupon Exchangeable Bonds

Trip.com Group Filed 2024 Annual Report on Form 20-F

Trip.com Group Limited to Report First Quarter of 2025 Financial Results on May 19, 2025 U.S. Time

Trip.com Group Limited Reports Unaudited First Quarter of 2025 Financial Results

Trip.com Group to Hold Annual General Meeting on June 30, 2025

Trip.com Group Announces Repurchase Right Notification for 1.50% Exchangeable Senior Notes due 2027

Trip.com Group Announces Updates on Its Investments in MakeMyTrip

BIDU

Airbnb

Atour Lifestyle Holdings Limited - American Depositary Shares

Atour Lifestyle Holdings

Booking Holdings

Choice Hotels International, Inc. Common Stock

Choice Hotels Intl

Expedia Group

Global Business Travel Group, Inc. Class A Common Stock

Global Business Travel

GreenTree Hospitality Group Ltd. American depositary shares, each representing one Class A ordinary share

GreenTree Hospitality Gr

Hyatt Hotels Corporation Class A Common Stock

Hyatt Hotels

Hilton Grand Vacations

Hilton Worldwide Holdings Inc. Common Stock

Hilton Worldwide Holdings

H World Group Limited - American Depositary Shares

H World Group

Intercontinental Hotels Group American Depositary Shares (Each representing one Ordinary Share)

Comments

Trip.com Group

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL